Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Blood (2025) 146 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2025-2999

Published: 2025

Journal Articles

Evolving insights and changes in survival of erdheim-chester disease over time

Blood (2025) 146 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2025-2990

Published: 2025

Journal Articles

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2025-2563

Published: 2025

Journal Articles

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 473.

https://doi.org/10.1182/blood-2025-473

Published: 2025

Journal Articles

Autologous stem cell transplantation and real-world outcomes in angioimmunoblastic T-cell lymphoma: A national cohort study

Yu Tao, Ayo Falade, Richard Godby, Steven Hwang, N. Nora Bennani, Stephen Ansell, Grzegorz Nowakowski, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 3640.

https://doi.org/10.1182/blood-2025-3640

Published: 2025

Journal Articles

Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Marian Abdelmalek, Bethany Horton, Emily Ayers, Craig Portell, Thomas Cropley, Prem Batchala, Ipsita Pal, John Manavalan, Owen O'Conner, Enrica Marchi

Blood (2025) 146 (Supplement 1): 5417.

https://doi.org/10.1182/blood-2025-5417

Published: 2025

Journal Articles

Mutational landscape of adult xanthogranuloma

Blood (2025) 146 (Supplement 1): 7339.

https://doi.org/10.1182/blood-2025-7339

Published: 2025

Journal Articles

The molecular landscape of patients with malignant histiocytosis

Alanis Rodriguez-Rosario, Jithma Abeykoon, N. Nora Bennani, Karen Rech, Mithun Shah, Aishwarya Ravindran, Aldo Acosta Medina, Gordon Ruan, Dongni Yi, Saurabh Zanwar, Gaurav Goyal, Ronald Go

Blood (2025) 146 (Supplement 1): 7335.

https://doi.org/10.1182/blood-2025-7335

Published: 2025

Journal Articles

Large language model for abstraction of CAR-T therapy toxicities data

Blood (2025) 146 (Supplement 1): 6139.

https://doi.org/10.1182/blood-2025-6139

Published: 2025

Journal Articles

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Blood (2025) 146 (Supplement 1): 3641.

https://doi.org/10.1182/blood-2025-3641

Published: 2025

Journal Articles

Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study

Blood (2025) 146 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2025-3635

Published: 2025

Journal Articles

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Blood (2025) 146 (Supplement 1): 6760.

https://doi.org/10.1182/blood-2025-6760

Published: 2025

Journal Articles

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Blood (2025) 146 (Supplement 1): 5439.

https://doi.org/10.1182/blood-2025-5439

Published: 2025

Journal Articles

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Deepa Jagadeesh, Stefan Barta, Seunghee Margevicius, Jonathan Brammer, Jeanette Comstock, Pingfu Fu, Rahul Mishra, Montreh Tavakkoli, Alma Habib, Imran Nizamuddin, Tiffany Chang, Melissa Pulitzer, Cesar Virgen, Sharina Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2025-5433

Published: 2025

Journal Articles

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Blood (2025) 146 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2025-6131

Published: 2025

Journal Articles

Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients ≥60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405

Craig Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher Reynolds, Priyank Patel, Michael Robertson, Brad Kahl

Blood (2025) 146 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2025-3574

Published: 2025

Journal Articles

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.

Muhammad Saad Hamid, Ashley McCook-Veal, Jeffrey Switchenko, Neha Mehta-Shah, Neha Akkad, Luis Malpica, Danielle Wallace, Evelyn Orlando, Jia Ruan, Brooj Abro, Melissa Larson, James Cerhan, Christopher Flowers, Georgios Pongas, Eric Mou, N. Nora Bennani, Pamela Allen

Blood (2025) 146 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2025-1870

Published: 2025

Journal Articles

Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2025-5894

Published: 2025

Journal Articles

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Alanis Enid Rodriguez-Rosario, Aldo Adrian Acosta Medina, N. Nora Bennani, Gaurav Goyal, Aishwarya Ravindran, Karen L Rech, Gordon J Ruan, Mithun V Shah, Dongni Yi, Saurabh Zanwar, Jithma P Abeykoon, Ronald S Go

Blood (2024) 144 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2024-204398

Published: 2024

Journal Articles

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Blood (2024) 144 (Supplement 1): 4564.

https://doi.org/10.1182/blood-2024-205474

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Evolving insights and changes in survival of erdheim-chester disease over time

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Autologous stem cell transplantation and real-world outcomes in angioimmunoblastic T-cell lymphoma: A national cohort study

Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma

Mutational landscape of adult xanthogranuloma

The molecular landscape of patients with malignant histiocytosis

Large language model for abstraction of CAR-T therapy toxicities data

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients ≥60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.

Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only